scispace - formally typeset
R

Rob A. E. M. Tollenaar

Researcher at Leiden University Medical Center

Publications -  300
Citations -  21817

Rob A. E. M. Tollenaar is an academic researcher from Leiden University Medical Center. The author has contributed to research in topics: Breast cancer & Colorectal cancer. The author has an hindex of 65, co-authored 273 publications receiving 18630 citations. Previous affiliations of Rob A. E. M. Tollenaar include Leiden University & Loyola University Medical Center.

Papers
More filters
Journal ArticleDOI

Genome-wide association study identifies novel breast cancer susceptibility loci

Douglas F. Easton, +109 more
- 28 Jun 2007 - 
TL;DR: To identify further susceptibility alleles, a two-stage genome-wide association study in 4,398 breast cancer cases and 4,316 controls was conducted, followed by a third stage in which 30 single nucleotide polymorphisms were tested for confirmation.
Journal ArticleDOI

Large-scale genotyping identifies 41 new loci associated with breast cancer risk

Kyriaki Michailidou, +220 more
- 01 Apr 2013 - 
TL;DR: A meta-analysis of 9 genome-wide association studies, including 10,052 breast cancer cases and 12,575 controls of European ancestry, and identified 29,807 SNPs for further genotyping suggests that more than 1,000 additional loci are involved in breast cancer susceptibility.
Journal ArticleDOI

Association analysis identifies 65 new breast cancer risk loci

Kyriaki Michailidou, +396 more
- 02 Nov 2017 - 
TL;DR: A genome-wide association study of breast cancer in 122,977 cases and 105,974 controls of European ancestry and 14,068 cases and 13,104 controls of East Asian ancestry finds that heritability of Breast cancer due to all single-nucleotide polymorphisms in regulatory features was 2–5-fold enriched relative to the genome- wide average.
Journal ArticleDOI

Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes

Nasim Mavaddat, +310 more
TL;DR: This PRS, optimized for prediction of estrogen receptor (ER)-specific disease, from the largest available genome-wide association dataset is developed and empirically validated and is a powerful and reliable predictor of breast cancer risk that may improve breast cancer prevention programs.